Suppr超能文献

术前全身免疫炎症指数预测胸腺瘤根治性切除术后的预后。

Preoperative systemic immune-inflammation index for predicting the prognosis of thymoma with radical resection.

机构信息

Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.

Department of Cardiothoracic Surgery, Children's Hospital of Nanjing Medical University, Nanjing, China.

出版信息

Thorac Cancer. 2023 May;14(13):1192-1200. doi: 10.1111/1759-7714.14854. Epub 2023 Mar 23.

Abstract

BACKGROUND

To investigate the clinical significance of preoperative systemic immune-inflammation index (SII) in patients with thymoma who underwent radical resection.

METHODS

This retrospective study involved 425 patients with thymoma who underwent radical resection at the First Affiliated Hospital of Nanjing Medical University between September 1, 2008 and December 30, 2019. Data regarding routine preoperative blood tests and clinical features were collected to calculate and analyze the SII, platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR).

RESULTS

Univariate analysis indicated that age (p = 0.021), tumor size (p = 0.003), extended resection (p < 0.001), Masaoka-Koga stage (p < 0.001), PLR (p = 0.012), NLR (p = 0.041), and SII (p = 0.003) were related to patient prognosis. A higher SII (>345.83) was a significant independent prognostic factor in this cohort (p = 0.001, HR = 5.756, 95% CI: 2.144-15.457). Multivariate analysis showed that a high PLR was significantly associated with overall survival (OS) (p = 0.008, HR = 3.29, 95% CI: 1.371-7.896), while a high NLR was a significant independent prognostic factor for shorter OS (p = 0.024, HR = 2.654, 95% CI: 1.138-6.19). SII had an area under the curve (AUC) of 70.6% (AUC = 0.706) exceeding the predictive value for PLR (AUC = 0.678) and NLR (AUC = 0.654).

CONCLUSION

Preoperative SII can predict the prognosis of thymoma patients who have undergone radical resection but further multicenter prospective studies are needed to investigate the role of SII in thymoma.

摘要

背景

探讨胸腺肿瘤患者根治性切除术前全身免疫炎症指数(SII)的临床意义。

方法

本回顾性研究纳入 2008 年 9 月 1 日至 2019 年 12 月 30 日在南京医科大学第一附属医院行根治性切除术的 425 例胸腺肿瘤患者。收集常规术前血液检查和临床特征数据,计算并分析 SII、血小板与淋巴细胞比值(PLR)和中性粒细胞与淋巴细胞比值(NLR)。

结果

单因素分析表明,年龄(p=0.021)、肿瘤大小(p=0.003)、扩大切除术(p<0.001)、Masaoka-Koga 分期(p<0.001)、PLR(p=0.012)、NLR(p=0.041)和 SII(p=0.003)与患者预后相关。该队列中,SII 较高(>345.83)是显著的独立预后因素(p=0.001,HR=5.756,95%CI:2.144-15.457)。多因素分析显示,高 PLR 与总生存(OS)显著相关(p=0.008,HR=3.29,95%CI:1.371-7.896),而高 NLR 是 OS 较短的独立预后因素(p=0.024,HR=2.654,95%CI:1.138-6.19)。SII 的曲线下面积(AUC)为 70.6%(AUC=0.706),超过了 PLR(AUC=0.678)和 NLR(AUC=0.654)的预测值。

结论

术前 SII 可预测胸腺肿瘤患者根治性切除术后的预后,但需要进一步进行多中心前瞻性研究来探讨 SII 在胸腺肿瘤中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5991/10151138/64df2f9d9d6c/TCA-14-1192-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验